1259375
Last Update Posted: 2017-04-17
Recruiting has ended
All Genders accepted | 18 Years + |
24 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma
Primary Objectives
- To evaluate the Response Rate (RR) for amrubicin in patients with metastatic or advanced sarcoma as first line therapy.
- To evaluate Progression Free Survival (PFS).
Secondary Objectives
- To assess the safety and tolerability of amrubicin in this patient population.
- To evaluate whether certain histologic subtypes of sarcoma demonstrate a differential response to amrubicin.
- To investigate quality of response with radiographic evaluation using both Response Evaluation Criteria In Solid Tumors (RECIST) and Choi criteria.
- To evaluate overall survival (OS).
Eligibility
Relevant conditions:
Soft Tissue Sarcoma
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov